S2 E7: A Between the Biotech Waves Conversation with Bobby Gaspar

Today’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options for severe genetic disorders.
As the co-founder and current CEO of Orchard Therapeutics, recently acquired by Kyowa Kirin, Bobby has been at the forefront of advancing gene therapy, particularly in hematopoietic stem cell gene therapy. His groundbreaking work includes some of the earliest studies in patients suffering from severe primary immune deficiencies, propelling these therapies into late-stage clinical trials and bringing hope to countless patients around the world.
Recently recognized on the inaugural TIME100 Health list in 2024, Bobby holds a dual role as a Venture Partner with F-Prime Capital in London, further showcasing his strategic vision in the biotech landscape. His leadership extends beyond Orchard, as he chairs the board of directors at Eligo Biosciences.
An honorary professor of pediatrics and immunology at the University College London, Bobby is dedicated to improving diagnosis and treatment for conditions like metachromatic leukodystrophy through innovative screening and education initiatives.
Join us as we explore Bobby's inspiring journey, his insights into the future of gene therapy, and the ways he is influencing human health on a global scale.